Inspection Record

New Vitalis Pharmacy LLC — FDA 483 Findings

US FDAInspected 2023-07-05Published 2023-11-01 11 findingsAseptic processing and sterility assuranceEquipment and facilityOther quality systemContamination control

Inspectors Ucheabuchi C Chudi-NwankworThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Use of processing aides not intended for pharmaceutical use in sterile drug production.

2Aseptic processing and sterility assurance

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

3Equipment and facility

Use of a sporicidal agent in the facility's ISO 5 areas and classified areas was lacking.

4Aseptic processing and sterility assurance

Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.

5Other quality system

Failure to conduct post-use filter-integrity testing on filters used to sterilize drug products.

6Aseptic processing and sterility assurance

Smoke studies were inadequately performed under dynamic conditions.

7Other quality system

HEP A filters are not sealed around the perimeter.

8Other quality system

Use of a disinfectant in a manner insufficient to achieve adequate levels of disinfection.

9Other quality system

Use of non-sterile cleaning wipes in the ISO 5 area.

10Contamination control

Personnel infrequently sanitized gloves to prevent contamination.

11Equipment and facility

The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.

About this record

Extracted automatically from the document US FDA published on 2023-11-01. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

New Vitalis Pharmacy LLC company profile — full history US FDA documents, 2023 Go to Findings search